Close this search box.

Papa succeeds Miller as Emergent’s CEO

ARTICLE | Management Tracks

Plus: Paratus names Heah as CEO and updates from Jazz, Arvinas, KaliVir, Celcuity, QuidelOrtho, Turnstone and PhRMA

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

February 21, 2024 11:54 PM UTC

Emergent BioSolutions Inc. (NYSE:EBS) named Joseph Papa as president and CEO, succeeding Haywood Miller who is stepping down as interim CEO. Papa was CEO and chairman at Bausch + Lomb Corp. (NYSE:BLCO) where he led the company’s 2022 IPO. Emergent, which makes the opioid overdose treatment Narcan naloxone and medical countermeasures against infectious diseases, said Papa will oversea an era of “returning to growth” at the company.

Paratus Sciences Corp., which is leveraging bat biology to treat human inflammatory and metabolic diseases, named Theresa Heah as CEO. Heah was president and CEO of Intergalactic Therapeutics Inc…